High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma
Marie‐Hélène Delfau‐Larue(Inserm), Eva Hoster(Zimmer Biomet (Germany)), Catherine Thiéblemont(Assistance Publique – Hôpitaux de Paris), Martin Dreyling(LMU Klinikum), Josette Brière(Assistance Publique – Hôpitaux de Paris), Olivier Casasnovas, Olivier Hermine(Délégation Paris 5), Elizabeth Macintyre(Université Paris Cité), Fabrice Jardin(Inserm), Gilles Salles(Université Claude Bernard Lyon 1), Françoise Berger(Hôpital Lyon Sud), Wolfgang Hiddemann(Christian-Albrechts-Universität zu Kiel), Pierre Feugier(Centre Hospitalier Régional et Universitaire de Nancy), Michael Unterhalt, Corinne Haïoun, Christiane Pott(University Hospital Schleswig-Holstein), Vincent Ribrag(Institut Gustave Roussy)
Cited by 157
Related Papers
<i>LMO2</i> -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
|Science|2003|3.5k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
|Journal of Clinical Investigation|2008|1.8k